Tumor antigen-specific adaptive immunity induction via mRNA vaccination

The phrase "Tumor antigen-specific adaptive immunity induction via mRNA vaccination" does not refer to a single molecule or receptor but rather describes a **therapeutic strategy**. This approach uses messenger RNA (mRNA) vaccines that encode specific tumor antigens—often patient-specific neoantigens—to induce an adaptive immune response against cancer. The process involves designing synthetic mRNAs that code for selected tumor antigens; these are delivered into host cells where they are translated into proteins. The resulting proteins are processed into peptide fragments and presented on major histocompatibility complex (MHC) molecules, activating cytotoxic CD8+ T cells and helper CD4+ T cells. This leads to targeted destruction of tumor cells expressing the encoded antigens and can also stimulate B cell-mediated antibody production[1][2]. This entry is **not a canonical molecular target** such as a receptor or enzyme; it refers instead to an immunological process enabled by therapeutic technology. Therefore, it should not be classified as a druggable target in the conventional sense. If you need information about specific targets within this strategy—such as "tumor-associated antigen," "neoantigen," "MHC class I molecule," or others—please specify so structured data can be provided for those entities.

Induction of tumor antigen-specific immune responses by delivering mRNA encoding tumor antigens to host cells, leading to translation of the encoded protein, processing into peptide epitopes, and presentation on MHC molecules to activate T cells and stimulate antibody production[1][2].